165 related articles for article (PubMed ID: 37422772)
1. Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.
Hilpert J; Groettrup-Wolfers E; Kosturski H; Bennett L; Barnes CLK; Gude K; Gashaw I; Reif S; Steger-Hartmann T; Scheerans C; Solms A; Rottmann A; Mao G; Chapron C
Drugs R D; 2023 Sep; 23(3):221-237. PubMed ID: 37422772
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688.
Battista C; Shoda LKM; Watkins PB; Groettrup-Wolfers E; Rottmann A; Raschke M; Generaux GT
Clin Pharmacol Ther; 2023 Nov; 114(5):1023-1032. PubMed ID: 37501650
[TBL] [Abstract][Full Text] [Related]
3. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis.
Rižner TL; Penning TM
Pharmacol Res; 2020 Feb; 152():104446. PubMed ID: 31546014
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study.
Parke S; Gude K; Roth K; Messina F
BMC Womens Health; 2024 Jun; 24(1):353. PubMed ID: 38890641
[TBL] [Abstract][Full Text] [Related]
6. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J; Becker C; Taylor H; Carmona Herrera F; Donnez O; Horne A; Paszkowski M; Petraglia F; Renner SP; Patel A; Boolell M; Bestel E; Dolmans MM
Hum Reprod; 2024 Jun; 39(6):1208-1221. PubMed ID: 38648863
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
8. Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Li Y; Zheng Y; Xu B; Cai L; Feng S; Liu Y; Zhu Z; Yu Q; Guo H
Clin Pharmacokinet; 2023 Dec; 62(12):1739-1748. PubMed ID: 37838623
[TBL] [Abstract][Full Text] [Related]
9. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a novel pain management device, AT-04, for endometriosis-related pain: study protocol for a phase III randomized controlled trial.
Ishikawa H; Yoshino O; Taniguchi F; Harada T; Momoeda M; Osuga Y; Hikake T; Hattori Y; Hanawa M; Inaba Y; Hanaoka H; Koga K
Reprod Health; 2024 Jan; 21(1):12. PubMed ID: 38279180
[TBL] [Abstract][Full Text] [Related]
12. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
[TBL] [Abstract][Full Text] [Related]
13. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
14. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
15. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
16. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
BMC Womens Health; 2021 Jun; 21(1):250. PubMed ID: 34154590
[TBL] [Abstract][Full Text] [Related]
17. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
[TBL] [Abstract][Full Text] [Related]
18. Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study.
Lang J; Yu Q; Zhang S; Li H; Gude K; von Ludwig C; Ren X; Dong L
J Womens Health (Larchmt); 2018 Feb; 27(2):148-155. PubMed ID: 29083258
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
